Table 2.
HeLa BRCA1-HiBiT pilot screen hits
| Compound | Info | % Activity | Treatment | BScore |
|---|---|---|---|---|
| GSK-J4∗/J1 | Inhibition of histone H3K27 demethylase | 10.76938 | 4μM | −6.98975 |
| GSK-J4∗/J1 | Inhibition of histone H3K27 demethylase | 8.236465 | 4μM | −7.05242 |
| NVS-CECR2-1 | CECR2, histone acetyl-lysine reader | 1.46524 | 4μM | −8.57839 |
| NVS-CECR2-1 | CECR2, histone acetyl-lysine reader | 1.544393 | 4μM | −9.22119 |
| 5-azacytidine | Azacytidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases | 77.97886 | 1μM | −5.43611 |
| (+)-JQ1 | binds competitively to acetyl-lysine recognition motifs, or bromodomains | 63.77522 | 1μM | −5.34616 |
| A-485 | Histone Acetyltransferase Inhibitor | 132.6749 | 0.25μM | 5.699724 |
| LBH-589, Panobinostat | Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with an IC50 of 5 nM. Phase 3 | 68.50157 | 0.25μM | −7.98186 |